Voquezna Triple Pak and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Voquezna Triple Pak (amoxicillin / clarithromycin / vonoprazan).
Clarithromycin Food
Minor Food Interaction
Grapefruit juice may delay the gastrointestinal absorption of clarithromycin but does not appear to affect the overall extent of absorption or inhibit the metabolism of clarithromycin. The mechanism of interaction is unknown but may be related to competition for intestinal CYP450 3A4 and/or absorptive sites. In an open-label, randomized, crossover study consisting of 12 healthy subjects, coadministration with grapefruit juice increased the time to reach peak plasma concentration (Tmax) of both clarithromycin and 14-hydroxyclarithromycin (the active metabolite) by 80% and 104%, respectively, compared to water. Other pharmacokinetic parameters were not significantly altered. This interaction is unlikely to be of clinical significance.
References (1)
- Cheng KL, Nafziger AN, Peloquin CA, Amsden GW (1998) "Effect of grapefruit juice on clarithromycin pharmacokinetics." Antimicrob Agents Chemother, 42, p. 927-9
Switch to consumer interaction data
Voquezna Triple Pak drug interactions
There are 771 drug interactions with Voquezna Triple Pak (amoxicillin / clarithromycin / vonoprazan).
Voquezna Triple Pak disease interactions
There are 12 disease interactions with Voquezna Triple Pak (amoxicillin / clarithromycin / vonoprazan) which include:
- colitis
- mononucleosis
- diabetes
- PKU
- renal dysfunction
- hepatotoxicity
- renal dysfunction
- myasthenia gravis
- QT prolongation
- hemodialysis
- bone fractures
- mineral metabolism
Report options
More about Voquezna Triple Pak (amoxicillin / clarithromycin / vonoprazan)
- Voquezna Triple Pak consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: H. pylori eradication agents
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
